0000358654
Donate

Reimbursement status:
Full reimbursement

Cancer: Lymphocytic leukaemia

Indication:

Imatinib is indicated for the treatment of: - adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. - adult patients with relapsed or refractory Ph+ ALL as monotherapy.

Reimbursement information:

EPAR/SmPC

Drug programme

Details

ATC category :
L01XE
L01XE Protein kinase inhibitors
EMA approval status :
Approved
EMA approval date :
2006-09-13
EMA conditional? :
No
EMA orphan? :
No
EMA biological? :
No